Breast (Edinburgh, Scotland) · 2026
Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nozawa Kazuki, Iwata Hiroji, Mukohara Toru, Taira Tetsuhiko, Yoshimura Akiyo, Nagai Shigenori E, Hashimoto Jun, Matsuura Kazuo, Mizuno Toshiro, Shinden Yoshiaki, Yamamoto Mitsugu, Takano Toshimi, Wakahara Makoto, Terakawa Hirofumi, Yamanaka Takashi, Kojima Yasuyuki, Nakayama Takahiro, Hirakawa Yuji, Shiosakai Kazuhito, Tsurutani Junji
Аннотация
BACKGROUND: Trastuzumab deruxtecan (T-DXd) is a key treatment for HER2-positive metastatic breast cancer (mBC); however, data on T-DXd rechallenge remain limited.
PATIENTS AND METHODS: This post-hoc subgroup analysis evaluated T-DXd rechallenge in patients with HER2-positive mBC using data from EN-SEMBLE, a nationwide cohort study in Japan (N = 664).
RESULTS: Twenty-six patients were included. Median real-world progression-free survival, real-world time to treatment failure, and overall survival were 6.5, 4.9, and 14.2 months, respectively. The objective response rate was 27%. Patients who discontinued initial T-DXd without progressive disease had numerically longer real-world progression-free survival. No interstitial lung disease occurred during rechallenge.
CONCLUSION: T-DXd rechallenge may have clinical activity in selected patients with HER2-positive mBC.
CLINICAL TRIAL REGISTRATION NUMBER: jRCT1030220506.
PATIENTS AND METHODS: This post-hoc subgroup analysis evaluated T-DXd rechallenge in patients with HER2-positive mBC using data from EN-SEMBLE, a nationwide cohort study in Japan (N = 664).
RESULTS: Twenty-six patients were included. Median real-world progression-free survival, real-world time to treatment failure, and overall survival were 6.5, 4.9, and 14.2 months, respectively. The objective response rate was 27%. Patients who discontinued initial T-DXd without progressive disease had numerically longer real-world progression-free survival. No interstitial lung disease occurred during rechallenge.
CONCLUSION: T-DXd rechallenge may have clinical activity in selected patients with HER2-positive mBC.
CLINICAL TRIAL REGISTRATION NUMBER: jRCT1030220506.